1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The improvement in overall survival and progression-free survival from adding necitumumab was more pronounced in patients with EGFR-expressing tumours (median OS 11.7 vs 10.0 months; HR 0.79, 95% CI 0.69-0.92; P=0.002; median PFS 5.7 vs 5.5 months, HR 0.84, 95% CI 0.72-0.92; P=0.018).
“This improvement in OS and PFS was more pronounced in the group of patients with EGFR-expressing tumours (median OS 11.7 months versus 10.0 months; HR 0.79, 95% CI: 0.69-0.92;P = 0.002; median PFS 5.7 months versus 5.5 months, HR 0.84, 95% CI: 0.72-0.92;P = 0.018) [53].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [53]
Tumours without EGFR expression as assessed by IHC did not show any benefit from the addition of necitumumab.
“In a retrospective analysis, tumours without EGFR expression as assessed by IHC, did not show any benefit from the addition of necitumumab.”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited by
Sorted by citations
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631 · see citing works
New and emerging targeted treatments in advanced non-small-cell lung cancer
Hirsch, F. R., Suda, K., Wiens, J., & Bunn, P. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31473-8 · Cited by 493 · see citing works
Self-citationPeters, S., & Zimmermann, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-70253-7_3 · Cited by 1 · see citing works
Berchem, G., & Peters, S. (2024) · Springer eBooks · doi:10.1007/978-3-030-93702-7_3-1 · Cited by 1 · see citing works
- Authors
- Paz-Ares, L., Socinski, M. A., Shahidi, J., Hozak, R. R., Soldatenkova, V., Thatcher, N., & Hirsch, F.
- Affiliations
- Hospital Universitario 12 De Octubre (ES)
- University of Pittsburgh (US)
- Eli Lilly (United States) (US)
- Eli Lilly (Germany) (DE)
- The Christie Hospital (GB)
- University of Colorado Anschutz (US)
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 11
- Issue
- 4
- Pages
- S153
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2341407964
- Cited by
- 4
- References
- 0
- Citations by year
- 2024: 1 · 2018: 1 · 2016: 2
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- necitumumab, gemcitabine plus cisplatin, lung squamous cell carcinoma, stage IV NSCLC, first-line therapy, subgroup analysis, anti-EGFR therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
